FOSCARNET PACKAGE INSERT PDF

Name of the medicinal product. Foscavir 24 mg/ml Solution for Infusion. 2. Qualitative and quantitative composition. Foscarnet trisodium hexahydrate 24 mg /ml. Package leaflet: Information for the user. Foscavir®. 24 mg/ml Solution for Infusion foscarnet. M UK. Read all of this leaflet carefully before you start. Foscavir™ (Foscarnet Sodium) Injection Product Insert rubber latex has not been used in the manufacture of this device or drug container closure system.

Author: Kajizragore Togal
Country: China
Language: English (Spanish)
Genre: Education
Published (Last): 22 March 2010
Pages: 323
PDF File Size: 19.6 Mb
ePub File Size: 9.55 Mb
ISBN: 964-7-39280-261-9
Downloads: 33959
Price: Free* [*Free Regsitration Required]
Uploader: Kataur

Crizotinib has been associated with concentration-dependent QT prolongation.

Ihsert weakness, myopathy, myositis, rhabdomyolysis. Amylase increased, blood creatine phosphokinase increased. Nephrotoxicity is also possible in patients receiving oral vancomycin for pseudomembranous colitis, should systemic absorption occur through significantly altered GI mucosa. Minor When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as perphenazine.

Obtain electrocardiograms ECG and electrolyte concentrations before and periodically during treatment with foscarnet. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.

This reduction may also have a bearing on heart function e. Because of the potential for TdP, use of foscarnet with cisapride is contraindicated.

Renal impairment and symptomatic hypocalcaemia Trousseau’s and Chvostek’s signs have been observed during concurrent treatment with Foscavir and i. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although pacjage have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction.

  CVAVR TUTORIAL PDF

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as apomorphine. Moderate Drugs such as foscarnet may increase the risk of developing peripheral neuropathy or other zalcitabine-associated adverse events by interfering with the renal clearance of zalcitabine and thereby raising systemic drug exposure.

Vemurafenib has also been associated with QT prolongation. The safety of foscarnet in pregnancy has not been established, so it should be used only when clearly needed. The mean volume of distribution of foscarnet at steady state varies between inzert. In addition, there are postmarketing reports of TdP with trazodone. Major There have been postmarketing reports of QT prolongation and torsade de pointes TdP during treatment with sertraline and the manufacturer of sertraline recommends avoiding concurrent use with drugs known to prolong the QTc interval.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as levofloxacin. Minor When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as fluphenazine.

After the first dose, the hydration fluid should be administered concurrently with each drug foscarnett.

Foscavir (foscarnet sodium) dose, indications, adverse effects, interactions from

Hypertension, hypotension, thrombophlebitis a. To prevent irritation and ulceration, close attention to personal hygiene is recommended and cleaning of the genital area after each micturition is recommended. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as atomoxetine. Major When foscarnrt, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as ondansetron.

  FUTURES AND FROSTING CHOCOLATE LOVERS #2 PDF

PDR Search

Because of the potential for TdP, use of foscarnet with dronedarone is contraindicated. If coadministration is necessary, monitor ECG and serum electrolytes. Moderate Monitor for changes in serum creatinine and phosphorus if tenofovir is administered in combination with nephrotoxic agents, such as foscarnet.

Drugs that decrease renal function may also increase concentrations of tenofovir. Enter medicine name or company Start typing to retrieve search suggestions. Major The risk of renal toxicity may be increased if foscarnet is used in conjunction with other nephrotoxic agents such as aminoglycosides. Major Avoid coadministration of ribociclib with foscarnet due to an increased risk for QT prolongation and torsade de pointes TdP.

Foscavir 24 mg/ml Solution for Infusion

Neither is foscarnet compatible with solutions containing calcium. Foscarnet selectively inhibits the viral-specific DNA polymerases and reverse transcriptases at the pyrophosphate-binding site. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as bedaquiline.

Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: